COLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION

CollPlant adds LightSolver’s CEO to its board as it closes the LightSolver deal and moves into photonic high‑performance computing alongside its biotech business.

Rhea-AI Summary

CollPlant Biotechnologies (CLGN) appointed Dr. Ruti Ben Shlomi, CEO and Co‑Founder of LightSolver, to its Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver announced on September 3, 2026.

LightSolver develops a proprietary Laser Processing Unit (LPU), an all‑optical, energy‑efficient photonic computing platform designed to accelerate computationally intensive workloads in scientific simulation, engineering, optimization and Physical AI. CollPlant states that Dr. Ben Shlomi's deep expertise in photonic computing and entrepreneurship will support the commercialization of this newly acquired technology.

With the LightSolver acquisition, CollPlant expands from regenerative medicine into advanced high‑performance computing, aiming to address demanding workloads in aerospace, defense and Physical AI while continuing its collagen-based 3D bioprinting, tissue repair and medical aesthetics activities.

Market Context

CLGN's September 3 acquisition completion was followed by -0.61% over 24 hours, versus +8.38% after ...

Analysis

CLGN's September 3 acquisition completion was followed by -0.61% over 24 hours, versus +8.38% after the August 31 announcement. That contrast adds context; the active F-3 resale registration and warrant-linked shares remain risks to monitor.

Key Figures

Appointment Date: September 4, 2026 Professional Experience: Over 15 years LightSolver Founded: 2020 +1 more

4 metrics

Appointment Date September 4, 2026 Board appointment announcement

Professional Experience Over 15 years Quantum, atomic, molecular physics and photonic computing

LightSolver Founded 2020 Co-founded by Dr. Ruti Ben Shlomi

Bioprinting Dimension 3D Tissue and organ bioprinting

Historical Context

5 past events · Latest: Sep 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 03	Acquisition completion	Positive	-0.6%	Acquisition completed; equity-centric transaction included shares, warrants and a $5 million investment.
Sep 01	Reverse split	Negative	-7.6%	One-for-ten reverse split took effect for split-adjusted trading on September 4.
Aug 31	LightSolver acquisition	Positive	+8.4%	Definitive LightSolver acquisition announced with shares, warrants and 2028 commercial availability target.
Jun 30	Private placement	Negative	-4.8%	A $2.6 million private placement priced shares and warrants at $0.34.
May 29	Earnings report	Negative	-0.7%	Q1 revenue fell to $73,000 while net loss widened to $3.1 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The two acquisition-related events diverged, with the announcement followed by +8.38% and completion followed by -0.61%; other recent events had negative reactions.

Key Terms

photonic computing, all-optical computing, 3d bioprinting, recombinant human collagen

4 terms

photonic computing technical

"LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise"

Photonic computing uses pulses of light instead of moving electrons to carry out calculations and move information, like replacing electrical wiring with tiny beams of light on a computer chip. It matters to investors because light-based chips promise much faster data processing and lower power use for tasks like large-scale AI and data centers, potentially creating new markets and competitive advantages — but the technology is still emerging and carries development and scaling risks.

all-optical computing technical

"integrating a proprietary all-optical computing architecture"

A computing approach that carries out logic and data processing using light (photons) instead of electric currents, typically with lasers, optical fibers, waveguides, and photonic components. Because light can move and switch without the resistive heating and certain delays of electrical wiring, all-optical designs promise higher speeds, lower energy loss, and different scaling trade-offs—factors that affect the cost, performance, and market potential of next-generation data centers, telecom hardware, and specialized processors.

3d bioprinting medical

"with a focus on 3D bioprinting of tissues and organs"

3D bioprinting is a manufacturing technique that uses printer-like equipment to place living cells and supportive materials layer by layer to create tissues or organ-like structures, similar to building a model one thin slice at a time. It matters to investors because successful bioprinted products could create new medical therapies, reduce lab time and costs, and open markets in drug testing and transplant alternatives, while also carrying long development timelines and regulatory risk.

recombinant human collagen medical

"products are based on its recombinant human collagen produced"

Collagen produced by inserting human collagen genes into cells or microorganisms so they manufacture the same protein sequence found in people; the product is purified from those cultured cells rather than taken from animal tissue. It matters to investors because it is a scalable, standardized source of human-sequence collagen used in medical products (wound care, implants, cosmetics and drug delivery), and its production method affects manufacturing cost, regulatory review, intellectual property and market differentiation—like making a recipe in a factory instead of harvesting it from different farms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology

REHOVOT, Israel, Sept. 4, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq: CLGN) today announced the appointment of Dr. Ruti Ben Shlomi, Chief Executive Officer and Co-Founder of LightSolver Ltd. ("LightSolver"), to CollPlant's Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver, as announced on September 3, 2026.

LightSolver is pioneering a new generation of high performance computing based on the physics of light. Its proprietary Laser Processing Unit (LPU), an energy-efficient, pure photonic computing platform that uses coupled lasers to perform computation, is designed to accelerate computationally intensive workloads across scientific simulation, engineering, optimization and Physical AI.

"We are delighted to welcome Dr. Ruti Ben Shlomi to CollPlant's Board of Directors," said Yehiel Tal, Chairperson and Chief Executive Officer of CollPlant. "Ruti is an accomplished physicist and entrepreneur whose pioneering work in photonic computing has established LightSolver at the forefront of deep-tech innovation. Her deep scientific expertise and entrepreneurial vision will be invaluable to our Board as CollPlant advances LightSolver's commercialization and builds its position in high-performance and photonic computing."

Dr. Ruti Ben Shlomi commented, "I am honored to join CollPlant's Board of Directors as we begin this next chapter. The completion of this transaction creates an important opportunity to accelerate LightSolver's transition from technology validation to commercialization and help establish photonic computing as a new computing layer for some of the world's most demanding computational workloads. I look forward to working closely with the Board and executive team to as we advance this next phase of LightSolver's development and create long-term value for our shareholders."

Dr. Ruti Ben Shlomi is the CEO and Co-Founder of LightSolver. She is an expert physicist with over 15 years of experience spanning quantum, atomic, and molecular physics, photonic computing and technology leadership. Prior to co-founding LightSolver in 2020, Dr. Ben Shlomi conducted groundbreaking research at the Weizmann Institute of Science, where she built ultra-cold atom and cold ion systems to study complex quantum signatures. Earlier in her career, she served as a process engineer at Intel Corporation.

Dr. Ben Shlomi holds a Ph.D. in Quantum and Atomic/Molecular Physics from the Weizmann Institute of Science, an M.Sc. in Physics from Ben-Gurion University of the Negev, and a B.Sc. in Biophysics from Bar-Ilan University.

About CollPlant

CollPlant is a pioneering technology company operating at the forefront of both regenerative medicine and advanced high-performance computing. Following the strategic acquisition of LightSolver, CollPlant has expanded its footprint into the deep-tech sector, integrating a proprietary all-optical computing architecture known as the Laser Processing Unit (LPU). This bold diversification positions the Company to address some of the world's most computationally intensive workloads across aerospace, defense, and Physical AI, while continuing to drive its core biotech innovations. 

In the healthcare sector, CollPlant is ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant-based genetic engineering technology, addressing indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing.

For more information about CollPlant, visit www.CollPlant.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the acquisition of LightSolver by CollPlant; the anticipated benefits, strategic rationale and growth opportunities arising from the transaction; LightSolver becoming a subsidiary of CollPlant; the future development, commercialization and market adoption of LightSolver's Laser Processing Unit (LPU) technology; and the future prospects, business plans and growth strategies of CollPlant, LightSolver and the combined business. Forward-looking statements can be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "may," "should," "could," "might," "seek," "target," "will," "project," "continue" and similar expressions or the negative of such terms. These forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the ability of the parties to satisfy the conditions to closing the transaction and consummate the transaction on the anticipated timeline or at all; the risk that the anticipated benefits of the transaction are not realized, or are not realized within the expected timeframe; risks associated with integrating LightSolver's business, operations and personnel; LightSolver's ability to achieve anticipated technological and commercial milestones; uncertainties regarding market acceptance and adoption of LightSolver's technology; the ability to develop and commercialize LightSolver's products and technology successfully; the ability to establish and expand strategic collaborations and commercial relationships; competition and technological developments; intellectual property risks; the availability of capital; CollPlant's ability to maintain compliance with Nasdaq listing requirements; general market, industry, economic and geopolitical conditions; and other risks and uncertainties described in CollPlant's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent Reports on Form 6-K. Forward-looking statements speak only as of the date of this press release. CollPlant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact Information:

CollPlant  
Eran Rotem
Deputy CEO & CFO
eran@collplant.com
+972.73.232.5600

LightSolver Ltd.  
Dr. Ruti Ben Shlomi
Founder & CEO 
ruti@lightsolver.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-appoints-dr-ruti-ben-shlomi-to-its-board-of-directors-following-closing-of-lightsolver-acquisition-302870018.html

SOURCE CollPlant

FAQ

What board change did CollPlant (CLGN) announce after closing the LightSolver acquisition?

CollPlant appointed Dr. Ruti Ben Shlomi, Chief Executive Officer and Co‑Founder of LightSolver, to its Board of Directors. The appointment is effective immediately following the completion of CollPlant's acquisition of LightSolver announced on September 3, 2026.

Who is Dr. Ruti Ben Shlomi, newly appointed to the CollPlant (CLGN) board?

Dr. Ruti Ben Shlomi is the CEO and Co‑Founder of LightSolver, a physicist with over 15 years of experience in quantum, atomic and molecular physics, photonic computing and technology leadership, with prior research at the Weizmann Institute of Science and earlier work as a process engineer at Intel.

What does LightSolver, acquired by CollPlant (CLGN), specialize in?

LightSolver is described as pioneering high‑performance computing based on the physics of light. Its proprietary Laser Processing Unit (LPU) is a pure photonic, energy‑efficient computing platform using coupled lasers to accelerate demanding workloads in scientific simulation, engineering, optimization and Physical AI.

How does the LightSolver acquisition change CollPlant’s (CLGN) business focus?

Following the LightSolver acquisition, CollPlant expands from regenerative medicine into advanced high‑performance and photonic computing. The company aims to address computationally intensive workloads in aerospace, defense and Physical AI, while continuing its recombinant human collagen‑based 3D bioprinting, tissue repair and medical aesthetics activities.

What role does photonic computing play in CollPlant’s (CLGN) strategy after acquiring LightSolver?

CollPlant highlights LightSolver’s all‑optical Laser Processing Unit as a new computing layer for very demanding workloads. The company says integrating this photonic computing technology supports the transition from technology validation to commercialization and complements its existing biotech innovations.

What are Dr. Ruti Ben Shlomi’s academic qualifications relevant to her role at CollPlant (CLGN)?

Dr. Ben Shlomi holds a Ph.D. in Quantum and Atomic/Molecular Physics from the Weizmann Institute of Science, an M.Sc. in Physics from Ben‑Gurion University of the Negev, and a B.Sc. in Biophysics from Bar‑Ilan University, supporting her expertise in photonic and quantum systems.